Minova Life Science

Minova life sciences - Pharmaceutical company

Tenlimax-M500 Tablets

COMPOSITION – Teneligliptin 20mg & Metformin Hydrochloride 500mg(Extended Release) Tablets

Tenlimax-M500 Tablets


  • A novel DPP-4 inhibitor with a preferable profile in terms of long-term efficacy and safety.
  • Provides strongest binding to DPP-4 enzymes as compared to other gliptins.
  • Gives potent and sustained effects on glycemic control and reduces diabetic complications.
  • ┬áProvides cardioprotection by improving left ventricular function and endothelial dysfunction without QT prolongation. Int J Basic Cin Pharmacol 2016:52):229-234
  • Effectively improves B-cell function and decreases insulin resistance.
  • Normalizes daily blood glucose fluctuations by suppressing post-prandial hyperglycemia at all three meals daily.
  • Shows significant improvement in lipid profiles along with improvement in blood glucose & HbA1c level.
  • Effectively Enhances adiponectin levels to regulate insulin sensitivity & energy homeostasis.
  • Teneligliptin 20 mg once daily is more potent than voglibose 0.2 mg tid, or vildagliptin 50 mg qd
  • Does not require dose adjustment for diabetic patients with end-stage renal disease and in hepatic patients.

Explore other products

Scroll to Top